2023 World Conference on Lung Cancer (Posters)-P2.16. Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-Stage Small Cell Lung Cancer: PEERS Phase 2 Trial

P2.16. Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-Stage Small Cell Lung Cancer: PEERS Phase 2 Trial - PDF(Slides)

Back to course

Pdf Summary

The poster presents data from the PEERS phase 2 trial, which is evaluating the combination of pembrolizumab, lenvatinib, and chemotherapy as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC). The study aims to assess the efficacy and safety of this treatment regimen in previously untreated patients with ES-SCLC.<br /><br />The combination of immune checkpoint inhibitors (ICIs) and chemotherapy is already a standard of care for ES-SCLC patients. Lenvatinib is a multiple receptor tyrosine kinase inhibitor that has shown synergistic efficacy with ICIs in preclinical and clinical studies.<br /><br />The PEERS trial is an ongoing multicenter, open-label, single-arm phase 2 trial being conducted in Spain. The study started in November 2022 and is estimated to be completed by July 2027. The safety run-in (part 1) of the trial has been completed, and data presented in the poster show that the combination of pembrolizumab, lenvatinib, and chemotherapy was well-tolerated and showed preliminary evidence of antitumor activity in the six patients included in this part of the study.<br /><br />The study design includes an induction phase of four cycles, followed by maintenance treatment with pembrolizumab and lenvatinib. The patients are being closely monitored for safety and efficacy endpoints, including progression-free survival (PFS), objective response rate (ORR), and overall survival (OS).<br /><br />The results from the safety run-in showed manageable safety and tolerability, and the preliminary efficacy data demonstrated an ORR of 66.7% in the six patients evaluated. No dose-limiting toxicities were observed, and the most common adverse events were fatigue, diarrhea, and neutrophil count decrease.<br /><br />The poster concludes that the combination of pembrolizumab, lenvatinib, and chemotherapy shows promising activity in previously untreated ES-SCLC patients. The ongoing phase 2 expansion of the PEERS trial will further evaluate the efficacy and safety of this treatment regimen in a larger cohort of patients.<br /><br />The authors disclose their affiliations and financial support from various pharmaceutical companies involved in the study. The ClinicalTrials.gov identifier for the PEERS trial is NCT05384015.

Asset Subtitle

Noemí Reguart Aransay

Meta Tag

Speaker Noemí Reguart Aransay

Topic SCLC & Neuroendocrine Tumors: Trials in Progress

Keywords

PEERS phase 2 trial

pembrolizumab

lenvatinib

chemotherapy

extensive-stage small cell lung cancer

efficacy

safety

immune checkpoint inhibitors

tyrosine kinase inhibitor

preclinical and clinical studies